Washington D.C., August 11, 2026 – In a landmark legislative achievement that promises to reshape the landscape of epilepsy care and research across the United States, the U.S. Senate unanimously passed the National Plan for Epilepsy Act (S. 494) on August 4, 2026. This monumental decision, celebrated today by Epilepsy Alliance America, marks a historic stride towards establishing a coordinated federal strategy to confront the complex challenges faced by millions of Americans living with epilepsy.
n
The Act aims to dramatically improve epilepsy care, accelerate groundbreaking research, significantly reduce epilepsy-related deaths, and ultimately enhance the quality of life for an often-underserved community. Its passage reflects years of unwavering dedication and relentless advocacy from individuals living with epilepsy, their families, caregivers, healthcare professionals, researchers, and a vast network of epilepsy organizations nationwide.
n
Main Facts: A Historic Leap Forward for Epilepsy Care
n
The National Plan for Epilepsy Act represents a pivotal moment in public health policy, moving epilepsy from a fragmented approach to a cohesive, federally coordinated strategy. Its unanimous passage in the Senate underscores a powerful bipartisan consensus on the urgent need for comprehensive action.
n
Unanimous Senate Approval
n
The unanimous vote on S. 494 on August 4, 2026, signals a rare moment of unity in a often-divided political climate. This resounding support from all members of the U.S. Senate demonstrates a profound recognition of the widespread impact of epilepsy and the critical necessity for a national, integrated response. The bipartisan leadership of Senators Eric Schmitt and Amy Klobuchar was instrumental in shepherding this legislation through the upper chamber, garnering the broad support needed for its successful passage. This collective endorsement reflects an understanding that epilepsy is not merely a medical condition but a multifaceted challenge affecting individuals, families, and the broader healthcare system, demanding a strategic, unified approach.
n
The Vision Behind the National Plan
n
At its core, the National Plan for Epilepsy Act mandates the federal government to undertake a comprehensive review of all existing epilepsy programs. This review will serve as the foundation for identifying significant gaps in services, outcomes, and research efforts, paving the way for data-driven recommendations to address unmet needs. The proposed National Plan will focus on several critical pillars:
n
- n
- Research: Fostering innovation and discovery to better understand the causes, mechanisms, and potential cures for epilepsy.
- Diagnosis: Improving early and accurate diagnosis, reducing diagnostic delays that can impact treatment effectiveness.
- Treatment: Expanding access to diverse and effective treatment options, including pharmacotherapy, surgery, dietary therapies, and neuromodulation.
- Awareness: Launching national campaigns to combat stigma, educate the public, and ensure timely intervention.
- Mortality Prevention: Implementing strategies to reduce Sudden Unexpected Death in Epilepsy (SUDEP) and other epilepsy-related fatalities.
- Quality of Life: Addressing the holistic needs of individuals, including mental health support, employment assistance, and social integration.
n
n
n
n
n
n
n
Crucially, the legislation emphasizes the importance of ongoing input from those with lived experience – individuals with epilepsy, their caregivers, healthcare providers, researchers, advocates, and relevant federal agencies. This inclusive framework ensures that the plan remains responsive to the real-world needs and challenges of the epilepsy community.
n
A Decade of Dedicated Advocacy
n
This legislative triumph is not an overnight success but the culmination of years, indeed decades, of tireless advocacy. It represents the perseverance of countless individuals and organizations who have dedicated their lives to elevating the voices and needs of the epilepsy community. From grassroots campaigns to sophisticated lobbying efforts, the journey to this Senate vote has been marked by a relentless pursuit of equity, understanding, and comprehensive support for those affected by epilepsy. This collective effort highlights the power of sustained advocacy in driving meaningful policy change.
n
Chronology: The Journey to Senate Passage
n
The path to the Senate’s unanimous vote on the National Plan for Epilepsy Act has been a long and arduous one, marked by strategic legislative maneuvering, robust committee review, and an unwavering commitment from advocates.
n
Roots of the Initiative: Early Advocacy Efforts
n
The concept of a national, coordinated strategy for epilepsy is not new. For many years, various epilepsy organizations, patient groups, and medical professionals have underscored the fragmented nature of epilepsy care and research in the U.S. These early calls for action often highlighted the disparities in access to specialized care, the lack of uniform data collection, and the persistent underfunding of epilepsy research compared to other neurological conditions. The Epilepsy Community Consensus Priorities, drafted earlier this year, played a crucial role in synthesizing these disparate needs into a unified legislative agenda, providing a clear roadmap for policymakers. This foundational work laid the groundwork for the legislative proposal, crystallizing the community’s collective vision into actionable policy points.
n
Legislative Introduction and Committee Review
n
The National Plan for Epilepsy Act (S. 494) was formally introduced in the Senate, championed by Senators Eric Schmitt (R-MO) and Amy Klobuchar (D-MN). Their bipartisan collaboration signaled early on the potential for broad support. Following its introduction, the bill was referred to the powerful Senate Health, Education, Labor and Pensions (HELP) Committee. This committee, responsible for legislation concerning public health and education, undertook a rigorous review process. On July 22, the HELP Committee approved a Manager’s Amendment to the bill. This amendment, a common legislative tool, allowed for technical adjustments and enhancements to the bill’s framework while meticulously preserving its core purpose and objectives. These refinements often incorporate feedback from various stakeholders, experts, and legislative counsel, strengthening the bill’s enforceability and effectiveness without altering its fundamental intent. The committee’s approval was a critical step, signifying that the bill was ready for consideration by the full Senate.
n
Pivotal Senate Vote: A Unified Front
n
The unanimous passage on August 4, 2026, was the culmination of these efforts. The absence of dissenting votes is a powerful testament to the compelling case made by advocates and the undeniable need for the proposed national strategy. This unity across the political spectrum demonstrates a shared recognition of the significant public health burden posed by epilepsy and the potential for a federal plan to deliver tangible improvements. The swift and decisive vote in the Senate reflects not only the legislative acumen of its sponsors but also the deep resonance of the issue with policymakers.
n
The Road Ahead: House Consideration
n
While the Senate passage is a monumental victory, the legislative journey is far from over. The National Plan for Epilepsy Act must now be considered and passed by the U.S. House of Representatives before it can be sent to the President for signature into law. Epilepsy Alliance America has already signaled its intention to work closely with congressional champions in the House, including Representatives Jim Costa (CA-21) and Greg Murphy, M.D. (NC-3), to build momentum and secure its passage before the end of the current congressional term. The focus now shifts to mobilizing support within the House, replicating the bipartisan success achieved in the Senate.
n
Supporting Data: The Urgent Need for a National Strategy
The imperative for a national strategy for epilepsy is underscored by compelling data illustrating the condition’s widespread prevalence, profound socio-economic burden, and significant gaps in current care and public understanding.
The Scope of Epilepsy in America
Epilepsy is one of the most common neurological conditions globally, affecting approximately 3.4 million people in the United States, including around 470,000 children. This makes it more prevalent than Parkinson’s disease, multiple sclerosis, and cerebral palsy combined. Each year, an estimated 150,000 new cases are diagnosed. The economic burden of epilepsy is staggering, with direct and indirect costs estimated to be in the tens of billions of dollars annually. These costs encompass healthcare expenditures for diagnosis, treatment, and management, as well as lost productivity due to seizures, associated comorbidities, and premature mortality. Beyond the statistics, epilepsy manifests in diverse forms, from generalized tonic-clonic seizures to subtle focal aware seizures, making its impact highly individualized and often unpredictable. The sheer scale of individuals affected, combined with the varied clinical presentations, necessitates a coordinated and comprehensive national response.
Gaps in Current Care and Research
Despite advances in medical science, significant gaps persist in epilepsy care and research. A substantial portion of individuals with epilepsy, estimated at around 30-40%, continue to experience uncontrolled seizures despite available treatments, highlighting the urgent need for novel therapies and personalized medicine approaches. Access to specialized epilepsy centers and neurologists is unevenly distributed across the country, creating disparities in care, particularly in rural or underserved urban areas.
Furthermore, epilepsy carries a significant risk of premature mortality. Sudden Unexpected Death in Epilepsy (SUDEP) is a devastating reality for many families, claiming thousands of lives annually, yet awareness and preventative strategies remain insufficient. The stigma associated with epilepsy continues to be a formidable barrier, impacting social integration, employment opportunities, and mental health. Many individuals report feeling isolated, discriminated against, and misunderstanding from the public, which often delays diagnosis or prevents them from seeking adequate care. The lack of standardized data collection across different healthcare systems also hinders robust epidemiological studies and effective public health interventions. These multifaceted gaps underscore why a national plan, rather than piecemeal initiatives, is essential.
The Power of Lived Experience: Advocacy in Action
The genesis and momentum behind the National Plan for Epilepsy Act are deeply rooted in the lived experiences of those affected by the condition. Thousands of advocates across the country have transformed their personal struggles into a powerful collective voice. They have shared poignant stories of diagnostic delays, the emotional toll of uncontrolled seizures, the financial strain of ongoing treatment, the impact of stigma on daily life, and the devastating reality of epilepsy-related deaths. These personal narratives, conveyed through countless meetings with elected officials, participation in advocacy days, signing support letters, and raising awareness in their communities, have been instrumental. They have humanized the statistics, compelling lawmakers to understand that behind every data point is an individual’s struggle and a family’s hope for a better future. This grassroots mobilization exemplifies the profound impact that sustained, personal advocacy can have on the legislative process, proving that collective voices can indeed drive monumental change.
Official Responses: Voices of Hope and Determination
The passage of S. 494 has elicited strong reactions of gratitude and renewed commitment from key stakeholders, reflecting the deep personal and professional investment in this legislative effort.
Epilepsy Alliance America’s Leadership: Gundell and Gallipoli
Epilepsy Alliance America (EAA) has been at the forefront of this advocacy push, and its leadership expressed immense gratitude and determination following the Senate vote. Liza Gundell, Board Chair of Epilepsy Alliance America, lauded the bipartisan leadership of Senators Schmitt and Klobuchar, stating, "The Senate’s unanimous support demonstrates a growing recognition that epilepsy deserves a coordinated national response. For too many individuals and families, epilepsy brings challenges that extend far beyond seizures, including barriers to care, stigma, financial burdens, and concerns about safety and quality of life. A National Plan for Epilepsy will help ensure that these challenges are addressed through a thoughtful, comprehensive, and collaborative strategy." Her words underscore the holistic vision of the Act, aiming to tackle not just the medical aspects but also the broader socio-economic and psychological burdens of epilepsy.
Lisa Gallipoli, Executive Director of Epilepsy Alliance America, while celebrating the achievement, also issued a clear call to continued action. "The passage by the Senate of the National Plan for Epilepsy is a great achievement; but our work is not done! Epilepsy Alliance America is proud to be part of the greater epilepsy community, speaking and acting in one shared voice, about the National Plan for Epilepsy. We will continue to mobilize our network to ensure that the House of Representatives follows the lead of the Senate before the end of the Congressional term." Her statement highlights the organization’s commitment to seeing the bill through to final enactment, recognizing that the battle is only half won.
Bipartisan Congressional Support: Senators Schmitt and Klobuchar
While not directly quoted in the provided text, the bipartisan leadership of Senators Eric Schmitt and Amy Klobuchar is repeatedly acknowledged as critical to the bill’s success. Their ability to bridge political divides and unite their colleagues around a common cause speaks volumes about the compelling nature of the National Plan for Epilepsy. Their joint sponsorship and advocacy demonstrate that improving public health outcomes for millions of Americans can transcend partisan politics when the need is clearly articulated and broadly understood. Their commitment has been instrumental in translating years of advocacy into tangible legislative progress.
The Personal Imperative: Amanda Mitchell’s Testimony
The human element of this legislative effort is powerfully encapsulated by the statement from Amanda Mitchell, MPH, an Epilepsy Alliance America Board member and a member of the National Plan for Epilepsy Committee. As the parent of a child with epilepsy, her advocacy is deeply personal. "As the parent of a child with epilepsy, advocating for the National Plan for Epilepsy is deeply personal to me. I know just how desperately our community needs the investments in comprehensive research, effective treatments, improved access to care, and increased support. It has been a privilege to add my voice to those in the epilepsy community who have pushed for this change for many years. I look forward to continuing to support this work until the plan is enacted into law, and we see its benefits for the millions of Americans living with epilepsy." Her testimony vividly illustrates the direct impact of epilepsy on families and the profound hope that this legislation brings. Her involvement in drafting The Epilepsy Community Consensus Priorities earlier this year further solidifies her integral role in shaping the very framework of the Act.
The Continuing Legislative Push: Representatives Costa and Murphy
Looking ahead, the focus shifts to the House of Representatives. Epilepsy Alliance America has identified Representatives Jim Costa (CA-21) and Greg Murphy, M.D. (NC-3) as key congressional champions who will lead the charge for the bill’s passage in the House. Their involvement is crucial for replicating the bipartisan success achieved in the Senate. Their commitment to the cause signals that momentum is building and that there is a strong foundation of support to push the legislation across the finish line before the end of the year.
Implications: Transforming the Landscape of Epilepsy in America
The enactment of the National Plan for Epilepsy Act would usher in a transformative era for epilepsy care, research, and public understanding, addressing long-standing disparities and fostering a more supportive environment for those living with the condition.
Enhanced Research and Innovation
A coordinated national plan will significantly bolster research efforts by identifying critical funding gaps, fostering inter-institutional collaboration, and prioritizing areas of unmet need. This could lead to accelerated discovery of new diagnostic tools, more effective and personalized treatments, and ultimately, a better understanding of the causes and potential cures for epilepsy. Federal coordination can streamline research protocols, facilitate data sharing, and encourage innovative approaches that might otherwise be overlooked or underfunded in a fragmented system. It will also likely attract more talent to the field of epilepsy research, ensuring a robust pipeline of future breakthroughs.
Improved Diagnosis and Treatment Pathways
The Act’s focus on reviewing existing programs and identifying gaps will inevitably lead to recommendations for improved diagnosis and treatment pathways. This could mean more standardized screening protocols, enhanced training for primary care physicians to recognize epilepsy symptoms earlier, and increased access to specialized epilepsy centers for complex cases. By ensuring that individuals receive timely and accurate diagnoses, the plan can prevent prolonged periods of uncontrolled seizures, which can have long-term cognitive and developmental consequences. Furthermore, a national strategy can promote the dissemination of best practices for treatment, ensuring that all Americans, regardless of their location or socioeconomic status, have access to the most effective therapies available.
Addressing Health Disparities and Access to Care
One of the most profound implications of a national plan is its potential to address glaring health disparities. The review process will likely highlight geographical, racial, and socioeconomic inequities in access to epilepsy specialists, diagnostic technologies, and advanced treatments. Recommendations emerging from the plan can then be tailored to specifically target these disparities, perhaps through telehealth initiatives, expanded community outreach programs, or targeted funding for underserved areas. By identifying and rectifying these systemic inequalities, the Act can ensure more equitable access to high-quality epilepsy care for all Americans.
Reducing Mortality and Enhancing Quality of Life
The explicit focus on mortality prevention, particularly SUDEP, is a critical component of the plan. Increased awareness campaigns, research into risk factors, and the development of preventative strategies can save lives. Beyond mortality, the Act aims to enhance the overall quality of life for individuals with epilepsy. This includes addressing comorbidities such as depression and anxiety, supporting educational and vocational integration, and combating the pervasive stigma that often accompanies the condition. By fostering a more inclusive and understanding society, the plan can empower individuals with epilepsy to live fuller, more engaged lives, free from unnecessary barriers and discrimination.
Fostering Public Awareness and Reducing Stigma
A federally coordinated awareness campaign, as envisioned by the Act, can dramatically improve public understanding of epilepsy. Dispelling myths, educating about seizure first aid, and promoting empathy can reduce the stigma that often leads to social isolation and discrimination. Increased public awareness can also encourage earlier help-seeking behavior, leading to faster diagnoses and better outcomes. By normalizing epilepsy and presenting accurate information, the plan can create a more supportive environment for individuals living with the condition.
A Model for Collaborative Healthcare Policy
The National Plan for Epilepsy Act, with its emphasis on ongoing input from a diverse array of stakeholders, sets a powerful precedent for collaborative healthcare policy. It demonstrates how patient advocacy, medical expertise, and legislative action can converge to create comprehensive solutions for complex public health challenges. This model, if successful, could serve as a blueprint for addressing other chronic conditions that require a coordinated national response, highlighting the effectiveness of an inclusive, data-driven approach to health policy.
Call to Action: The Final Push for Enactment
Momentum is undeniably building, but the journey to fully enact the National Plan for Epilepsy Act is not yet complete. The unified voice that resonated in the Senate must now echo through the halls of the House of Representatives.
Mobilizing Grassroots Support
Epilepsy Alliance America is calling upon the entire epilepsy community to maintain and intensify its grassroots advocacy efforts. The power of individual stories and collective action has already proven effective in the Senate, and it will be equally crucial in the House. Advocates are urged to contact their U.S. Representatives, sharing personal testimonies, emphasizing the critical need for this legislation, and urging them to cosponsor and support the National Plan for Epilepsy Act. This direct engagement with elected officials is paramount to ensuring that the bill receives the attention and votes it needs for passage.
A Unified Vision for the Future
The vision of a nation where epilepsy is better understood, effectively treated, and no longer carries the burden of undue stigma is now within reach. The National Plan for Epilepsy Act represents a commitment to comprehensive care, cutting-edge research, and an improved quality of life for millions. As the bill moves to the House, the unified efforts of advocates, policymakers, and healthcare professionals will be essential to transform this historic Senate passage into a lasting legislative legacy. The future of epilepsy care in America hinges on this final push, ensuring that the promise of a national strategy becomes a tangible reality for all those affected.
Take action today: Ask your U.S. Representative to support the National Plan for Epilepsy Act.
[Link to action page: https://www.votervoice.net/EAA/campaigns/122944/respond]
